Heart Failure Society of America Annual Meeting

Muthiah Vaduganathan, MD, MPH, offers insight and perspective into a new annual report from the Heart Failure Society of America outlining trends in epidemiology and outcomes in heart failure.

Stephen Greene, MD, discusses trials, data, and themes to look for at the HFSA 2023 meeting.

A new initiative from the HFSA highlights key findings on heart failure prevalence, risk, mortality and hospitalization rates in the United States.

In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.

While better therapies exist to treat patients with heart failure with reduced ejection fraction, there are several hurdles preventing them from being implemented.

Doctors need to use their best judgement when deciding when to use cardiogenic shock devices for temporary mechanical support.

How recent trends in heart failure research have shown more priority to patient quality of life outcomes.

How does the broadened sacubitril/valsartan assessment influence the treating confidence of a clinician?

Shaquille O'Neal, EdD, and Elizabeth Ofili, MD, discuss how organizations and physicians are taking novel approaches to engage patients and non-patients about heart failure.

New findings from the trial show daily adherence to the fluid monitoring ReDS system dropped HF patient readmission risk by 58%.

Shaquille O'Neal and Elizabeth Ofili, MD, sit down to discuss Shaq Gets Real, which is a new campaign from Arbor Pharmaceuticals to increase awareness of the disparities in heart failure rates in the African American community.

After success in a recent clinical trial, dapagliflozin will soon be available to reduce the risk of heart failure in adults with heart failure reduced ejection fraction or preserved ejection fraction.

Elizabeth Ofili, MD, discusses the importance of annual meetings, such as HFSA 2019, for outreach and engaging patient populations about heart failure.

At the annual meeting dedicated to heart failure, investigators present nutritional recommendations for patients, which includes dietary consultations, bariatric surgery, and a reduction in saturated fats and sodium.

Shaquille O'Neal, Ed.D, and Elizabeth Ofili, MD, discuss using unconventional mediums to engage non-patients and spread awarness of heart failure — specifically in African Americans.

A proof of concept trial examining spironolactone for heart failure prevention presented at HFSA 2019 found spironolactone use did reduce PIIINP or that its impact on PIIINP was mitigated by galectin-3.

There are many options to treat heart failure for patients suffering from end stage kidney disease.

Results of the AMBER study, presented at HFSA 2019, found that patiromer can help improve spironolactone use while also reducing the prevalence of hyperkalemia.

While the benefits are clear, there are still some hurdles that remain preventing an increase in suggested dialysis frequency.

What was learned from the newest data for sacubitril/valsartan for HFrEF?

A study presented at HFSA 2019 Scientific Sessions found that virtual visits were a feasible option that could reduce no-show rates among heart failure patients following hospitalization.

How new dapagliflozin findings from ESC 2019 and HFSA 2019 shape our understanding of the SGLT-2 inhibitor's benefit.

Investigators present data during the HFSA meeting on how different types of meals at different time impact the body’s circadian rhythm.

Emerging mechanical therapy options have given life to a field which has gone under severe recharacterization in an era of increased obesity.

Hospital costs, length of stay, and even mortality were shown to be significantly cut in TAVR patients with comorbid heart failrue than those without, new data shows.

By doubling the recommended weekly dialysis, patients see a number of benefits, including a reduction in blood pressure and improvements in cardiovascular vibration.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.

Despite an embrace of greater patient populations by the FDA, cardiovascular research into stem cell therapy has been slow and burdened.

A six-month regimen of the oral therapy showed patients with out-of-proportion PH improved their six-minute walking test scores.

How do a pair of burgeoning agents influence endocrinology and renal outcomes in cardiovascular care?